<DOC>
	<DOCNO>NCT02340988</DOCNO>
	<brief_summary>The purpose study assess drug interaction potential time course effect oritavancin warfarin pharmacokinetics open label , single arm manner .</brief_summary>
	<brief_title>Drug-Drug Interaction Potential Orbactiv ( Oritavancin ) Co-Administered With Warfarin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Oritavancin</mesh_term>
	<criteria>1 . Subject able provide write informed consent initiation studyrelated procedure . 2 . Subject healthy male female adult 18 55 year age , inclusive . 3 . Subject body mass index ( BMI ) &lt; 45 kg/m2 . 4 . Subject good health base medical history physical examination finding . 5 . Female subject surgically sterile , postmenopausal , , childbearing potential , agree use least 2 acceptable method birth control ( e.g . prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , barrier method , abstinence ) male partner sterilization alone duration study 60 day study drug administration . 6 . Subject agree abstain caffeine theobromine containing product consumption Seville orange , grapefruit ( include grapefruit juice ) , broccoli , brussel sprout , charcoal grill meat , energy drink 48 hour study drug administration throughout clinical phase study . 1 . Has condition , include finding medical history prestudy assessment constitute risk contraindication participation study complete study . 2 . Positive breath test alcohol and/or positive urine test drug abuse Screening . 3 . Has history presence alcohol/drug abuse within 2 year . Alcohol abuse define regularly consume &gt; 3 units/day ( 21 unit per week men ) , &gt; 2 units/day ( 14 drinks/week ) woman . 1 unit alcohol define 4 % beer ( 330 mL ) , approximately 190 mL 67 % beer ( malt liquor ) , glass 40 % spirit ( 30 mL ) , glass wine ( 100 mL ) . 4 . Blood plasma donation within past 2 month . 5 . History hypersensitivity glycopeptide antibiotic ( similar chemical structure oritavancin ) excipients oritavancin . 6 . History hypersensitivity warfarin 4hydroxycoumarins , excipients warfarin . 7 . Participation clinical research study involve evaluation investigational drug device within 90 day prior enrollment and/or unwilling allow least two month participation another drug trial follow current trial . 8 . Treatment prescription OTC ( counter ) drug herbal nutritional supplement within 2 week Screening , exception acetaminophen/paracetamol minor headache . Subjects allow receive medication duration study ( except mention acetaminophen/paracetamol ) . Birth control hormone replacement also permit long take stable dose least three month Screening Visit remain stable duration study . 9 . Females pregnant nursing positive pregnancy test result screen . 10 . Males unwilling practice abstinence use acceptable method birth . control entire study period ( i.e . condom spermicide ) 11 . Known protein C protein S deficiency . 12 . Inflammatory Bowel Disease condition may decrease absorption warfarin . 13 . History bleed tendency ( e.g history menorrhagia , gastrointestinal bleeding ) . 14 . History heparininduced thrombocytopenia . 15 . Surgery within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>